NRx Pharmaceuticals (NRXP)
(Delayed Data from NSDQ)
$2.08 USD
+0.04 (1.96%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $2.08 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value A Growth C Momentum C VGM
NRx Pharmaceuticals, Inc. (NRXP) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$31.00 | $43.00 | $19.00 | 1,419.61% |
Price Target
Based on short-term price targets offered by two analysts, the average price target for NRx Pharmaceuticals, Inc. comes to $31.00. The forecasts range from a low of $19.00 to a high of $43.00. The average price target represents an increase of 1% from the last closing price of $2.04.
Analyst Price Targets (2 )
Broker Rating
NRx Pharmaceuticals, Inc. currently has an average brokerage recommendation (ABR) of 1.50 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by two brokerage firms. The current ABR compares to an ABR of 1.50 a month ago based on two recommendations.
Of the two recommendations deriving the current ABR, one is Strong Buy and one is Buy. Strong Buy and Buy each account for 50% of all recommendations. A month ago, Strong Buy made up 50%, while Buy represented 50%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/NRXP.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 1 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/5/2024 | H.C. Wainwright & Co. | Vernon Bernardino | Strong Buy | Strong Buy |
6/7/2024 | Ascendiant Capital Markets | Edward M Woo | Moderate Buy | Moderate Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.50 |
ABR (Last week) | 1.50 |
# of Recs in ABR | 2 |
Average Target Price | $31.00 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 96 of 253 |
Current Quarter EPS Est: | -0.81 |